Overview Request Sample Pages Request Customization Download PDF
You are viewing: France Protein Expression Market analysis
Part of: Protein Expression Market (Global)

The France Protein Expression Market was valued at $173.7 Million in 2026 and projected to reach to $257.5 Million by 2031, representing a compound annual growth rate of 8.2%. France's protein expression market is positioned for sustained growth through 2031, driven by increasing investments in biopharmaceutical research and the country's strategic focus on becoming a European life sciences leader.

France Protein Expression Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Protein Expression Market Trends and Insights

  • France is establishing itself as a key hub for biopharmaceutical research and development within Europe, driven by strong government support for life sciences innovation and a robust network of research institutions.
  • The growth trajectory in France reflects increasing demand for recombinant protein production, monoclonal antibody development, and therapeutic protein manufacturing across the country's expanding biotech sector. France's protein expression market benefits from significant investments in healthcare infrastructure and a skilled workforce specializing in molecular biology and protein engineering.
  • Between 2026 and 2031, France is expected to see accelerated adoption of advanced expression systems, including mammalian cell culture, bacterial expression platforms, and emerging cell-free technologies.
  • The country's strategic position within the European Union and its commitment to precision medicine initiatives position France as an attractive market for both established pharmaceutical companies and emerging biotechnology firms seeking to scale protein production capabilities..

Key Market Statistics

  • CAGR (2026-2031) 8.2% CAGR
  • Market Size, 2026 ~USD 173.7 Million
  • Forecast, 2031 ~USD 257.5 Million
  • Country France

France Protein Expression Market Overview

Market Size & Growth :

France's protein expression market is valued at USD 173.7 million in 2026 and is projected to reach USD 257.5 million by 2031, with a steady CAGR of 8.2%, reflecting strong demand for biopharmaceutical innovation.

European Biotech Hub :

France has emerged as a leading center for biopharmaceutical R&D in Europe, supported by substantial government funding, tax incentives, and a collaborative ecosystem of research institutions and private enterprises.

Research Infrastructure :

The country boasts a robust network of world-class research institutions, including CNRS, INSERM, and major universities, providing advanced facilities and expertise in protein expression technologies and therapeutic development.

Regulatory & Innovation Support :

France benefits from favorable EU regulatory frameworks and dedicated innovation programs that accelerate the development and commercialization of protein-based therapeutics and recombinant protein products.

France Protein Expression Market Dynamics

  • The expansion of contract research organizations (CROs) and contract manufacturing organizations (CMOs) specializing in protein expression is enhancing market accessibility for both domestic and international companies.
  • Government initiatives promoting biotechnology innovation and the presence of multinational pharmaceutical companies establishing R&D centers in France further strengthen market dynamics.
  • The growing demand for personalized medicine and advanced biologics is expected to accelerate adoption of cutting-edge protein expression platforms and technologies across French research and commercial sectors..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • France's protein expression market is valued at USD 173.7 million in 2026 and will reach USD 257.5 million by 2031, growing at 8.2% CAGR.
    • France benefits from strong government support for life sciences and a well-established network of research institutions driving market expansion.
    • Advanced expression systems including mammalian cell culture and cell-free technologies are accelerating adoption across France's biotech sector.
    • France's EU position and precision medicine initiatives attract both multinational pharma and emerging biotech companies to establish protein production operations.

    Protein Expression Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SOFTWARE (Type)
    Forecast Period 2026–2031
    Growth Rate CAGR of 8.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 5.13 (2026)
    Revenue Forecast (Billions) ~USD 7.65 (2031)
    Segments Covered Offering, Type, End User, Workflow, Scale Of Operation, Protein Modality, Application

    France Protein Expression Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Algal & Plant-Based Expression Systems
    • Algal-Based Expression Systems
    • Analytical Instruments
    • Bacillus Systems
    • Baculovirus Systems
    • Bioreactors & Fermenters
    • Cell-Free Expression Systems
    • Cho Cell Systems
    • Chromatography & Purification Consumables
    • Chromatography Systems
    • Cld Services
    • Cloning & Mutagenesis Kits
    • Competent Cells
    • Consumables
    • Culture Media & Supplements
    • Custom Protein Expression Services
    • E. Coli Lysate-Based Systems
    • E. Coli Systems
    • Expression Kits
    • Expression Vectors & Plasmids
    • Filtration & Separation Consumables
    • Filtration Systems
    • Gene Synthesis & Cloning Services
    • Hek 293 Cell Systems
    • Insect Cell Expression Systems
    • Instruments
    • Kits
    • Liquid Handling & Automation Systems
    • Mammalian Cell Expression Systems
    • Other Cell-Free Expression Systems
    • Other Consumables
    • Other Insect Cell Expression Systems
    • Other Instruments
    • Other Kits
    • Other Mammalian Cell Expression Systems
    • Other Prokaryotic Expression Systems
    • Other Reagents
    • Other Yeast Expression Systems
    • Pichia Systems
    • Process Development & Scale-Up Services
    • Prokaryotic Expression Systems
    • Reagents
    • Saccharomyces Systems
    • Software
    • Transduction & Transfection Reagents
    • Yeast Expression Systems

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    By Workflow

    • Cloning & Transfection
    • Extraction, Purification, And Characterization
    • Transcription, Translation, And Post-Translational Modification (Ptm)

    By Scale Of Operation

    • Discovery & Research Scale
    • Preclinical & Characterization Scale
    • Process Development & Pilot Scale

    By Protein Modality

    • Enzymes & Catalytic Proteins
    • Monoclonal Antibodies & Derivatives
    • Other Proteins
    • Recombinant Therapeutic Proteins
    • Vaccines

    By Application

    • Diagnostic Applications
    • Industrial Applications
    • Research Applications
    • Therapeutic Applications

    FRANCE: PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES10.711.112.313.414.615.917.318.88.8
    OTHER END USERS2.92.93.23.43.63.94.14.46.5
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES20.120.923.125.127.229.632.134.88.5
    TOTAL33.734.938.74245.549.353.557.98.4

    FRANCE: PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES34.63639.943.447.251.355.760.58.7
    CROS & CDMOS39.240.845.449.65458.964.269.89
    OTHER END USERS28.729.33234.236.438.941.544.26.7
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES49.45156.36165.871.276.9838.1
    TOTAL151.9157.1173.7188.1203.5220.3238.4257.58.2

    Target Audience

    • Biopharmaceutical Companies : Manufacturers and developers of protein-based therapeutics need France-specific market data to assess expansion opportunities, identify local partnerships, and optimize R&D investments in this growing European market.
    • Contract Research & Manufacturing Organizations : CROs and CMOs require detailed market insights to understand demand for protein expression services in France, benchmark capabilities against competitors, and identify growth opportunities with pharmaceutical clients.
    • Research Institutions & Universities : Academic and government research organizations need market intelligence to align protein expression research initiatives with commercial opportunities and secure funding for innovation projects in France.
    • Investors & Private Equity Firms : Investment professionals evaluating opportunities in French biotech require comprehensive market data to assess growth potential, identify acquisition targets, and make informed capital allocation decisions.
    • Technology & Equipment Suppliers : Vendors of protein expression platforms, reagents, and instrumentation need France-specific demand forecasts to prioritize market development, allocate sales resources, and customize product offerings for local customers.

    Key Companies in the France Protein Expression Market

    CompanyHQOwnershipStrongest segments
    PATHEON INCNetherlandsPrivate CompanyDrug Product Services (finished dosage manufacturing & packaging),Pharmaceutical Development Services,Drug Substance Services (small- and large-molecule APIs),
    NANOSTRING TECHNOLOGIES, INCUnited StatesPrivate CompanynCounter instruments and consumables (Pro, FLEX, SPRINT, CodeSets, panels, reagents),GeoMx DSP and spatial biology solutions,Prosigna and other in vitro diagnostic kits,
    BIOGENUnited StatesPublic CompanyMultiple Sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SPINRAZA and rare neuromuscular (SPINRAZA, QALSODY, SKYCLARYS),Alzheimer’s and neuropsychiatry (LEQEMBI, ZURZUVAE),
    SIGMA-ALDRICH CORPORATIONUnited StatesPrivate CompanyPharma and biopharma manufacturing (media, filtration, critical raw materials, safety testing),Research reagents and molecular biology (chemicals, biochemicals, functional genomics, protein biology),Analytical chemistry, diagnostics, and industrial microbiology,
    VIVA BIOTECH LTDChinaPublic CompanyDiscovery biology & structural biology services,Medicinal and synthetic chemistry & CADD,CDMO & CMC/filing services,
    CODEXIS, INC.United StatesPublic CompanyBiopharma process enzymes and custom engineering (CodeEvolver-based),ECO Synthesis and nucleic acid manufacturing solutions,Other life science and industrial enzyme applications,
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx instruments and related consumables,ExPERT STx instruments and related consumables,ExPERT GTx instruments and related consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, delivery equipment),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction),Life Sciences (research and analytical instruments, genomics),Diagnostics (clinical instruments and consumables),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical solutions (BLI, cytometry screening, PAT, live-cell imaging, SPR),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing),
    GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments and cellular analysis devices,In vitro diagnostics (including COVID-19),
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other / Software and Services,
    QIAGENNetherlandsPublic CompanySample technologies (extraction and purification consumables/instruments),PCR and enzymes (qPCR/dPCR instruments and reagents),Molecular diagnostic assays (TB, oncology, sexual and reproductive health, transplant/viral load),
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, equipment),Display glass substrates (LCD/OLED),Specialty materials and mobile consumer electronics glass,
    LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian and drug product CDMO),Advanced Synthesis (small molecules, HPAPIs, ADCs, bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
    FUJIFILM HOLDINGS CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative, cosmetics/supplements),Electronics (display, semiconductor, image sensors, functional films, storage),Business Innovation (office equipment, document services, graphic communications),
    SYNGENE INTERNATIONAL LIMITEDIndiaPublic CompanyDiscovery Services (chemistry, biology, computational),Development Services (preclinical, CMC, clinical development),Biologics and Specialty Modalities,
    LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (PE, EVA, LLDPE, UNIQABLE),Styrene-based resins (ABS, ASA, PS, EPS, SAN),Polycarbonate and engineering plastics (LUMID/LUXY, LUMILOY, LUPOL, LUPOY, etc.),

    PATHEON INC

    Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the life sciences sector.

    NANOSTRING TECHNOLOGIES, INC

    NanoString Technologies, Inc is a United States-based private company founded in 2003 with 550 employees specializing in life sciences technology.

    BIOGEN

    Biogen is a United States-based public company founded in 1978 with 7,500 employees engaged in biotechnology and pharmaceutical development.

    SIGMA-ALDRICH CORPORATION

    Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees providing life sciences products and services.

    VIVA BIOTECH LTD

    Viva Biotech Ltd is a China-based public company founded in 2008 with 2,169 employees providing drug discovery and development services.

    CODEXIS, INC.

    Codexis, Inc is a United States-based public company founded in 2002 with 146 employees focused on enzyme engineering and biocatalysis.

    MAXCYTE, INC

    MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees specializing in cell engineering technology.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc is a United States-based public company founded in 1956 with 125,000 employees serving the life sciences and laboratory sectors globally.

    MERCK KGAA

    Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees operating as a diversified pharmaceutical and chemical company.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees engaged in life sciences, diagnostics, and environmental solutions.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

    SARTORIUS AG

    Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees specializing in laboratory and bioprocess equipment.

    GENSCRIPT

    GenScript is a Hong Kong-based public company founded in 2002 with 6,165 employees providing biotechnology research services and products.

    TAKARA BIO INC.

    Takara Bio Inc is a Japan-based private company founded in 2002 with 1,779 employees specializing in biotechnology research tools and services.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc is a United States-based public company founded in 1952 with 7,450 employees manufacturing life sciences research and clinical diagnostics products.

    QIAGEN

    Qiagen is a Netherlands-based public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research solutions.

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services.

    CORNING INCORPORATED

    Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees manufacturing specialty glass and materials for life sciences applications.

    LONZA

    Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services.

    FUJIFILM HOLDINGS CORPORATION

    Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating across imaging, pharmaceuticals, and life sciences sectors.

    SYNGENE INTERNATIONAL LIMITED

    Syngene International Limited is an India-based public company founded in 1993 with 6,692 employees providing drug discovery and development services.

    LGC LIMITED

    LGC Limited is a South Korea-based public company founded in 1947 with 14,019 employees operating in life sciences and analytical testing services.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise market valuations and growth projections specific to France, enabling accurate budgeting, investment planning, and competitive positioning within the French protein expression sector.
    • Regulatory & Policy Insights : Understand France-specific regulatory frameworks, government support programs, and innovation incentives that directly impact market entry strategies and operational planning for protein expression businesses.
    • Competitive Landscape Analysis : Identify key players, CROs, CMOs, and research institutions operating in France, along with their capabilities and market positioning to inform partnership and acquisition strategies.
    • Growth Driver Identification : Discover France-specific factors driving market expansion, including research funding trends, pharmaceutical company investments, and emerging therapeutic areas demanding advanced protein expression solutions.
    • Strategic Market Entry Planning : Leverage detailed France market intelligence to develop targeted go-to-market strategies, identify distribution channels, and establish partnerships with local stakeholders in the biopharmaceutical ecosystem.

    Frequently asked questions

    What is the current size of France's protein expression market?

    France's protein expression market is estimated at USD 173.7 million in 2026 and is projected to grow to USD 257.5 million by 2031.

    What is the expected growth rate for France's protein expression market?

    France's protein expression market is expected to grow at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2031.

    What are the main drivers of growth in France's protein expression market?

    Key drivers include government support for life sciences innovation, a skilled workforce in molecular biology, increasing demand for recombinant proteins and monoclonal antibodies, and France's strategic position within the European Union.

    Which expression systems are gaining traction in France?

    Mammalian cell culture, bacterial expression platforms, and emerging cell-free technologies are all experiencing accelerated adoption across France's biotech sector between 2026 and 2031.

    Why is France an attractive market for protein expression companies?

    France offers strong healthcare infrastructure, a skilled scientific workforce, government backing for precision medicine initiatives, and access to the broader European market, making it ideal for both established and emerging biotech firms.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the protein expression market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global protein expression market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Protein Expression Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the protein expression market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Protein Expression Market : Top-Down and Bottom-Up Approach

    Protein Expression Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The protein expression market encompasses the technologies, products, and services required for protein production and analysis. This market includes various expression systems (mammalian, bacterial, yeast, algal, insect, and cell-free), reagents and instruments for transfection and cloning, growth reagents for cell culture during translation, and reagents and kits for downstream processes such as purification and characterization. It serves industries such as pharmaceuticals, biotechnology, academic & research institutes, CROs & CDMOs, and other industrial users, supporting applications in drug discovery, therapeutic development, and biochemical research, as well as other industries such as food and beverages, cosmetics, and textiles, among others.

    Key Stakeholders

    • Protein Expression Instrument & Reagent Manufacturers
    • Suppliers of Expression Systems
    • National and regional research boards and organizations
    • Research & development companies
    • Clinical research organizations (CROs)
    • Contract Manufacturing Organizations (CMOs)
    • Biotechnology companies
    • Research laboratories & academic institutes
    • Market research & consulting firms
    • Regulatory bodies

    Report Objectives

    • To define, describe, and forecast the protein expression market by offering, type, workflow, scale of operation, protein modality, application, product end user, service end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall protein expression market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia, United Arab Emirates, and the Rest of GCC) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Customization Options

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe protein expression market, by country
    • Further breakdown of the Rest of Asia Pacific protein expression market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Protein Expression Market Report

    Full forecast, segment splits, and company analysis for all Protein Expression Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status